Full text
Earnings transcript
Read the complete earnings call transcript.
4543
4543.T
Terumo Corporation
$2212
18.5
(0.84%)
| Exchange: | JPX |
| Market Cap: | 3.263T |
| Shares Outstanding: | 1.51B |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Instruments & Supplies | |||||
| CEO: | Hikaru Samejima | |||||
| Full Time Employees: | 30207 | |||||
| Address: |
| |||||
| Website: | https://www.terumo.co.jp |
Terumo Corporation is a global enterprise dedicated to the development, manufacturing, and distribution of a wide array of medical products and equipment. Its comprehensive operations are structured across three primary divisions: the Cardiac and Vascular Company, the Medical Care Solutions Company, and the Blood and Cell Technologies Company. The Cardiac and Vascular Company focuses on cardiovascular and neurovascular interventions. Its product portfolio encompasses a variety of devices, including angiographic guidewires, catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, and self-expanding peripheral stents, alongside advanced intravascular ultrasound systems and imaging catheters. This division also develops specialized devices for treating cerebral aneurysms, such as coils, stents, and intrasaccular devices, as well as embolization systems, aspiration catheters, and clot retrievers for ischemic stroke. Furthermore, it supplies critical components for cardiac surgery, including oxygenators and cardio-pulmonary bypass systems, in addition to artificial vascular and stent grafts. The Medical Care Solutions Company addresses a broad spectrum of general medical and patient care needs. Offerings include essential medical supplies like syringes, infusion and syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, and products for pain management and nutritional support, as well as adhesion barriers. This segment also produces consumer health monitoring devices such as blood glucose monitoring systems, disposable needles for pen-injectors, insulin patch pumps, blood pressure monitors, and digital thermometers. Moreover, it provides contract manufacturing services for pharmaceutical companies, specializing in prefilled syringes and devices like prefillable syringes and needles for pharmaceutical packaging. Finally, the Blood and Cell Technologies Company concentrates on products and systems for blood and cell management. Its offerings span blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, and advanced cell expansion systems. Established in 1921, the company was initially known as Sekisen Ken-onki Corporation before adopting its current name, Terumo Corporation, in October 1974. Terumo Corporation maintains its corporate headquarters in Tokyo, Japan.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 921,863,000 | 1,036,171,000 | 1,131,877,000 |
| Gross Profit | 454,173,000 | 532,779,000 | 594,676,000 |
| EBITDA | 219,660,000 | 242,510,000 | 276,917,000 |
| Operating Income | 134,196,000 | 179,022,000 | 184,739,000 |
| Net Income | 106,374,000 | 116,978,000 | 135,914,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Total Assets | 1,831,402,000 | 1,828,393,000 | 2,312,234,000 |
| Total Liabilities | 504,306,000 | 459,852,000 | 727,722,000 |
| Total Stockholders Equity | 1,327,090,000 | 1,368,535,000 | 1,584,509,000 |
| Total Debt | 268,548,000 | 213,957,000 | 379,796,000 |
| Cash and Cash Equivalents | 204,883,000 | 221,872,000 | 280,494,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Operating Cash Flow | 146,330,000 | 210,802,000 | 230,852,000 |
| Capital Expenditure | -60,727,000 | -68,617,000 | -85,213,000 |
| Free Cash Flow | 85,603,000 | 142,185,000 | 145,639,000 |
| Net Income | 106,374,000 | 116,978,000 | 135,914,000 |
| Net Change in Cash | 17,561,000 | 16,989,000 | 58,622,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2031 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 1,511,223,053.809 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 1,629,211,666.517 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 1,590,090,000 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 361,166,788.919 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 389,364,855.560 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 380,015,179.060 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 258,867,693.616 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 285,559,995.481 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 276,709,582.237 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 429,301,620.776 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 462,819,308.679 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 451,705,797.142 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 187.550 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 193.550 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 175.460 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 7 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 8 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about 4543.T valuation
Is Terumo Corporation (4543.T) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Terumo Corporation (4543.T) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is 4543.T a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether 4543.T trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is 4543.T’s P/E ratio?
You can see 4543.T’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for 4543.T?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is 4543.T a good long-term investment?
Whether 4543.T fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
4543.T
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0.84
Trading Metrics:
| Open: | 2199 | Previous Close: | 2193.5 | |
| Day Low: | 2186.5 | Day High: | 2236.5 | |
| Year Low: | 1900 | Year High: | 2818 | |
| Price Avg 50: | 2175.24 | Price Avg 200: | 2252.52 | |
| Volume: | 4.964M | Average Volume: | 5.841M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free